Drug-Induced Hematologic Syndromes
Open Access
- 7 July 2009
- journal article
- review article
- Published by Hindawi Limited in Advances in Hematology
- Vol. 2009, 1-11
- https://doi.org/10.1155/2009/495863
Abstract
Objective. Drugs can induce almost the entire spectrum of hematologic disorders, affecting white cells, red cells, platelets, and the coagulation system. This paper aims to emphasize the broad range of drug-induced hematological syndromes and to highlight some of the newer drugs and syndromes.Methods. Medline literature on drug-induced hematologic syndromes was reviewed. Most reports and reviews focus on individual drugs or cytopenias.Results. Drug-induced syndromes include hemolytic anemias, methemoglobinemia, red cell aplasia, sideroblastic anemia, megaloblastic anemia, polycythemia, aplastic anemia, leukocytosis, neutropenia, eosinophilia, immune thrombocytopenia, microangiopathic syndromes, hypercoagulability, hypoprothrombinemia, circulating anticoagulants, myelodysplasia, and acute leukemia. Some of the classic drugs known to cause hematologic abnormalities have been replaced by newer drugs, including biologics, accompanied by their own syndromes and unintended side effects.Conclusions. Drugs can induce toxicities spanning many hematologic syndromes, mediated by a variety of mechanisms. Physicians need to be alert to the potential for iatrogenic drug-induced hematologic complications.Keywords
This publication has 100 references indexed in Scilit:
- Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura: A Report From the SERF-TTP Research Group and the RADAR ProjectJournal of the American College of Cardiology, 2007
- Drug-Induced ThrombocytopeniaHematology/Oncology Clinics of North America, 2007
- Sweet's syndrome – a comprehensive review of an acute febrile neutrophilic dermatosisOrphanet Journal of Rare Diseases, 2007
- Current concepts in the pathophysiology and treatment of aplastic anemiaBlood, 2006
- Patients with quinine-induced immune thrombocytopenia have both “drug-dependent” and “drug-specific” antibodiesBlood, 2006
- Erythropoietin and blood dopingBritish Journal of Sports Medicine, 2006
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- Drug-Induced Thrombotic MicroangiopathyDrug Safety, 2001
- Drug-Induced Methaemoglobinaemia Treatment IssuesDrug Safety, 1996